臨床検査64巻12号

2020年12月発行

今月の特集1 血栓止血学のトピックス—求められる検査の原点と進化

がん関連血栓症

著者： 窓岩清治¹

所属機関： ¹東京都済生会中央病院臨床検査医学科

ページ範囲：P.1366 - P.1371

Point

●がん自体による血小板-血液凝固系の活性化や炎症反応に伴う線溶系の抑制は，がん関連血栓症（CAT）の一因となる．

●がんが診断された時点で血栓症の発症リスクを評価することは，予防策を講じるうえで重要である．

●静脈血栓塞栓症（VTE）の診断には，“検査前臨床的確率”やD-ダイマー値，造影CTなどの画像検査を組み合わせたアルゴリズムが用いられる．

●抗凝固薬の基本は，患者に生じた凝固亢進の病態を是正し，血栓の進展を防ぐことである．

参考文献

1）Walker AJ, Card TR, West J, et al：Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer　49：1404-1413，2013

2）Nakamura M, Miyata T, Ozeki Y, et al：Current venous thromboembolism management and outcomes in Japan. Circ J　78：708-717，2014

3）Timp JF, Braekkan SK, Versteeg HH, et al：Epidemiology of cancer-associated venous thrombosis. Blood　122：1712-1723，2013

4）日本循環器学会，日本医学放射線学会，日本胸部外科学会，他：2016-2017年度活動　肺血栓塞栓症および深部静脈血栓症の診断，治療，予防に関するガイドライン（2017年改訂版），2018（https://j-circ.or.jp/old/guideline/pdf/JCS2017_ito_h.pdf）（最終アクセス：2020年10月13日）

5）Boccaccio C, Comoglio PM：Genetic link between cancer and thrombosis. J Clin Oncol　27：4827-4833，2009

6）Geddings JE, Hisada Y, Boulaftali Y, et al：Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost　14：153-166，2016

7）Wahrenbrock M, Borsig L, Le D, et al：Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest　112：853-862，2003

8）Shirai T, Inoue O, Tamura S, et al：C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice. J Thromb Haemost　15：513-525，2017

9）Schumacher D, Strilic B, Sivaraj KK, et al：Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell　24：130-137，2013

10）Demers M, Wagner DD：Neutrophil extracellular traps: A new link to cancer-associated thrombosis and potential implications for tumor progression. Oncoimmunology　2：e22946，2013

11）Massberg S, Grahl L, von Bruehl ML, et al：Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med　16：887-896，2010

12）Cools-Lartigue J, Spicer J, McDonald B, et al：Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest　123：3446-3458，2013

13）Longstaff C, Varjú I, Sótonyi P, et al：Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones. J Biol Chem　288：6946-6956，2013

14）Petterson TM, Marks RS, Ashrani AA, et al：Risk of site-specific cancer in incident venous thromboembolism: a population-based study. Thromb Res　135：472-478，2015

15）Ay C, Pabinger I, Cohen AT：Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost　117：219-230，2017

16）Horsted F, West J, Grainge MJ：Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med　9：e1001275，2012

17）Cronin-Fenton DP, Søndergaard F, Pedersen LA, et al：Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer　103：947-953，2010

18）Khorana AA, Kuderer NM, Culakova E, et al：Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood　111：4902-4907，2008

19）Key NS, Khorana AA, Kuderer NM, et al：Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol　38：496-520，2020

20）Johnson ED, Schell JC, Rodgers GM：The D-dimer assay. Am J Hematol　94：833-839，2019

21）Wells PS, Anderson DR, Rodger M, et al：Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost　83：416-420，2000

22）Gibson NS, Sohne M, Kruip MJ, et al：Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost　99：229-234，2008

23）Le Gal G, Righini M, Roy PM, et al：Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med　144：165-171，2006

24）Hendriksen JM, Geersing GJ, Moons KG, et al：Diagnostic and prognostic prediction models. J Thromb Haemost　11（Suppl 1）：129-141，2013

25）Hutten BA, Prins MH, Gent M, et al：Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol　18：3078-3083，2000

26）Prandoni P, Lensing AW, Piccioli A, et al：Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood　100：3484-3488，2002

27）Yamashita Y, Morimoto T, Amano H, et al：Anticoagulation Therapy for Venous Thromboembolism in the Real World - From the COMMAND VTE Registry. Circ J　82：1262-1270，2018

28）Sakamoto J, Yamashita Y, Morimoto T, et al：Cancer-Associated Venous Thromboembolism in the Real World - From the COMMAND VTE Registry. Circ J　83：2271-2281，2019

29）Posch F, Königsbrügge O, Zielinski C, et al：Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res　136：582-589，2015

30）Raskob GE, van Es N, Verhamme P, et al：Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med　378：615-624，2018

31）Young AM, Marshall A, Thirlwall J, et al：Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol　36：2017-2023，2018

32）Agnelli G, Becattini C, Meyer G, et al：Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med　382：1599-1607，2020